Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) shares dropped 7.4% on Friday . The company traded as low as $40.03 and last traded at $42.77. Approximately 4,660,289 shares traded hands during trading, a decline of 12% from the average daily volume of 5,299,938 shares. The stock had previously closed at $46.17.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the stock. William Blair restated a "market perform" rating on shares of Tempus AI in a research note on Tuesday, February 25th. Bank of America raised their price objective on Tempus AI from $54.00 to $60.00 and gave the stock a "neutral" rating in a research note on Monday, March 3rd. Morgan Stanley raised their target price on shares of Tempus AI from $50.00 to $60.00 and gave the stock an "overweight" rating in a report on Thursday, March 6th. TD Cowen reaffirmed a "buy" rating and issued a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Finally, JPMorgan Chase & Co. downgraded shares of Tempus AI from an "overweight" rating to a "neutral" rating and boosted their price objective for the company from $50.00 to $55.00 in a research report on Tuesday, February 25th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $61.18.
Check Out Our Latest Stock Report on Tempus AI
Tempus AI Stock Performance
The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The stock's fifty day moving average is $57.54 and its two-hundred day moving average is $51.18.
Insider Buying and Selling at Tempus AI
In other Tempus AI news, Director Wayne A.I. Frederick sold 3,000 shares of the company's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $45.54, for a total transaction of $136,620.00. Following the completion of the sale, the director now directly owns 26,514 shares in the company, valued at $1,207,447.56. This represents a 10.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $60.00, for a total transaction of $826,200.00. Following the completion of the sale, the chief accounting officer now owns 57,237 shares in the company, valued at approximately $3,434,220. The trade was a 19.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,581,969 shares of company stock valued at $316,538,582 in the last three months.
Institutional Investors Weigh In On Tempus AI
Institutional investors have recently modified their holdings of the company. Operose Advisors LLC bought a new stake in shares of Tempus AI in the 4th quarter valued at $25,000. Farther Finance Advisors LLC bought a new stake in Tempus AI in the fourth quarter valued at $34,000. Prestige Wealth Management Group LLC increased its stake in Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock valued at $36,000 after purchasing an additional 965 shares in the last quarter. NewEdge Advisors LLC acquired a new position in shares of Tempus AI during the fourth quarter valued at about $49,000. Finally, First Horizon Advisors Inc. boosted its position in shares of Tempus AI by 207.9% during the 4th quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company's stock worth $55,000 after purchasing an additional 1,108 shares in the last quarter. 24.22% of the stock is owned by institutional investors.
About Tempus AI
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Featured Articles
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
